Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: Alternative subcellular enzyme compartmentation may contribute to carcinogenesis

Cancer Research

Volumn 65, Issue 9, 2005, Pages 3726-3734

  Leung, Yuet Kin ^a   Lau, Kin Mang ^a,b   Mobley, James ^a,c   Jiang, Zhong ^a   Ho, Shuk Mei ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Chinese University of Hong Kong   (Hong Kong)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZO[A]PYRENE DERIVATIVE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A1 1V; CYTOCHROME P450 1A1 WT; ESTRADIOL; ETHOXYRESORUFIN DEETHYLASE; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CAUSE OF DEATH; CELL IMMORTALIZATION; CELL NUCLEUS; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOPLASMIC RETICULUM; ENZYME LOCALIZATION; EPITHELIUM CELL; FEMALE GENITAL TRACT TUMOR; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL;

ALTERNATIVE SPLICING; BASE SEQUENCE; BENZO(A)PYRENE; CARCINOGENS; CELL LINE, TUMOR; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; CYTOCHROME P-450 CYP1A1; EPITHELIUM; ESTRADIOL; FEMALE; HUMANS; ISOENZYMES; MITOCHONDRIA; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; OVARY; RNA, MESSENGER; SUBCELLULAR FRACTIONS; TRANSFECTION;

EID: 18144383865     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3771     Document Type: Article

References (49)

1. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19:3-10.
2. Bosetti C, Negri E, Franceschi S, et al. Diet and ovarian cancer risk: a case-control study in Italy. Int J Cancer 2001;93:911-5.
3. Kuper H, Titus-Ernstoff L, Harlow BL, et al. Population based study of coffee, alcohol and tobacco use and risk of ovarian cancer. Int J Cancer 2000;88:313-8.
4. Marchbanks PA, Wilson H, Bastos E, et al. Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet Gynecol 2000;95:255-60.
5. Jeffy BD, Schultz EU, Selmin O, et al. Inhibition of BRCA-1 expression by benzo[a]pyrene and its diol epoxide. Mol Carcinog 1999;26:100-18.
6. Whitlock JP. Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 1999;39:103-25.
7. Davis BJ, Mccurdy EA, Miller BD, et al. Ovarian tumors in rats induced by chronic 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment. Cancer Res 2000;60:5414-9.
8. Pesatori AC, Consonni D, Tironi A, et al. Cancer in a young population in a dioxin-contaminated area. Int J Epidemiol 1993;22:1010-3.
9. Yager JD. Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 2000;67-73.
10. Russo J, Hasan LM, Balogh G, et al. Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J Steroid Biochem Mol Biol 2003;87:1-25.
11. Ho SM. Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 2003;1:73.
12. Murdoch WJ, Martinchick JF. Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention. Exp Biol Med (Maywood) 2004;229:546-52.
13. Crofts F, Taioli E, Trachman J, et al. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 1994;15:2961-3.
14. Terry KL, Titus-Ernstoff L, Garner EO, et al. Interaction between CYP1A1 polymorphic variants and dietary exposures influencing ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12:187-90.
15. Aktas D, Guney I, Alikasifoglu M, et al. CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm. Gynecol Oncol 2002;86:124-8.
16. Goodman MT, McDuffie K, Kolonel LN et al. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev 2001;10:209-16.
17. Caceres JF, Kornblihtt AR. Alternative splicing: Multiple control mechanisms and involvement in human disease. Trends Genet 2002;18:186-93.
18. Burset M, Seledtsov IA, Solovyev W. Analysis of canonical and non-canonical splice sites mammalian genomes. Nucleic Acids Res 2000;28:4364-75.
19. Tarn WY, Steitz JA. Pre-mRNA splicing: the discovery of a new spliceosome doubles the challenge. Trends Biochem Sci 1997;22:132-7.
20. Clark F, Thanaraj TA. Categorization and characterization of transcript-confirmed constitutively and alternatively spliced introns and exons from human. Hum Mol Genet 2002;11:451-64.
21. Haseloff J, Siemering KR. Prasher DC, et al. Removal of a cryptic intron and subcellular localization of green fluorescent protein are required to mark transgenic Arabidopsis plants brightly. Proc Natl Acad Sci U S A 1997;94:2122-7.
22. Tsao SW, Mok SC, Fey EG, et al. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res 1995;218:499-507.
23. Syed V, Ulinski G, Mok SC, et al. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001;61:6768-76.
24. Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U S A 1999;96:5722-7.
25. Leav I, Lau KM, Adams JY, et al. Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 2001;159:79-92.
26. Le Ferrec E, Lagadic-Gossmann D, Rauch C, et al. Transcriptional induction of CYP1A1 by oltipraz in human Caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent. J Biol Chem 2002;277:24780-7.
27. Gambone CJ, Hutcheson JM, Gabriel JL, et al. Unique property of some synthetic retinoids: activation of the aryl hydrocarbon receptor pathway. Mol Pharmacol 2002;61:334-42.
28. Wagner S, Chiosea S. Nickerson JA. The spatial targeting and nuclear matrix binding domains of SRm160. Proc Natl Acad Sci U S A 2003;100:3269-74.
29. Burke MD, Prough RA, Mayer RT. Characteristics of a microsomal cytochrome P-448-mediated reaction. Etboxyresorufin O-de-ethylation. Drug Metab Dispos 1977;5:1-8.
30. Mount SM, Steitz JA. Sequence of UI RNA from Drosophila melanogaster: implications for UI secondary structure and possible involvement in splicing. Nucleic Acids Res 1981;9:6351-68.
31. Nigg EA. Nucleocytoplasmic transport: signals, mechanisms and regulation. Nature 1997;386:779-87.
32. Neupert W. Protein import into mitochondria. Annu Rev Biochem 1997;66:863-917.
33. Black SD, Mould DR. Development of hydrophobicity parameters to analyze proteins which bear post- or cotranslational modifications. Anal Biochem 1991;193:72-82.
34. Szklarz GD, Paulsen MD. Molecular modeling of cytochrome P450 1A1: enzyme-substrate interactions and substrate binding affinities. J Biomol Struct Dyn 2002;20:155-62.
35. Ma Q. Induction of CYP1A1. The AhR/DRE paradigm: transcription, receptor regulation, and expanding biological roles. Curr Drug Metab 2001;2:149-64.
36. Pryor WA. Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. Environ Health Perspect 1997;105:875-82.
37. Schwarz D, Kisselev P, Cascorbi I, et al. Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants. Carcinogenesis 2001;22:453-9.
38. Maniatis T, Tasic B. Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature 2002;418:236-43.
39. Bresnick E. Drug metabolism: speculations on the future. Drug Metab Rev 1979;10:311-3.
40. 2-terminal-processed microsomal protein to mitochondria: a novel pathway for the biogenesis of hepatic mitochondrial P450MT2. J Cell Biol 1997;139:589-99.
41. Nebert DW, Negisbi M, Lang MA, et al. The Ah locus, a multigene family necessary for survival in a chemically adverse environment: comparison with the immune system. Adv Genet 1982;21:1-52.
42. Wijnhoven SW, Kool HJ, van Oostrom CT, et al. The relationship between benzo[a]pyrene-induced mutagenesis and carcinogenesis in repair-deficient Cockayne syndrome group B mice. Cancer Res 2000;60:5681-7.
43. Chen SY, Lin JR, Darbha R, et al. Glycine N-methyltransferase tumor susceptibility gene in the benzo(a)pyrene-detoxification pathway. Cancer Res 2004;64:3617-23.
44. Garner El, Stokes EE, Berkowitz RS. et al. Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer. Cancer Res 2002;62:3058-62.
45. Millikan RC, Pittman GS, Tse CK, et al. Catechol-O-methyltransferase and breast cancer risk. Carcinogenesis 1998;19:1943-7.
46. Kristensen VN, Borresen-Dale AL. Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutat Res 2000;462:323-33.
47. Dawling S, Hachey DL, Roodi N, et al. In vitro model of mammary estrogen metabolism: structural and kinetic differences between catechol estrogens 2- and 4-hydroxyestradiol. Chem Res Toxicol 2004;17:1258-64.
48. Fecley KM. Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001;38:87-95.
49. Lee AJ, Cai MX, Thomas PE, et al. Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by 15 selectively expressed human cytochrome P450 isoforms. Endocrinology 2003;144:3382-98.